(Q44582795)

English

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment

scientific article published in September 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Serial minimal residual disease (MRD) analysis as a predictor of response duration in Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) during imatinib treatment (English)

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1 reference

based on heuristic

inferred from title

lymphoblastic leukemia

1 reference

based on heuristic

inferred from title

9

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

author name string

Scheuring UJ

1

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Pfeifer H

2

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Wassmann B

3

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Brück P

4

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Gehrke B

5

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Petershofen EK

6

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Gschaidmeier H

7

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Hoelzer D

8

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

publication date

1 September 2003

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

17

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

9

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

1700-1706

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

Detection of chimeric BCR-ABL genes in acute lymphoblastic leukaemia by the polymerase chain reaction.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

Philadelphia chromosome-positive acute lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

Long-term follow-up of 23 patients with Philadelphia chromosome-positive acute lymphoblastic leukemia treated with allogeneic bone marrow transplant in first complete remission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

Allogeneic stem cell transplantation for acute lymphocytic leukemia in adults

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

Therapy with imatinib mesylate (Glivec) preceding allogeneic stem cell transplantation (SCT) in relapsed or refractory Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome/Bcr-Abl-positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

Ph(+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

Quantification of minimal residual disease in patients with BCR-ABL-positive acute lymphoblastic leukaemia using quantitative competitive polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

21 January 2018

Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

7 January 2021

based on heuristic

inferred from DOI database lookup

Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of the Philadelphia chromosome on minimal residual disease in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

7 January 2021

based on heuristic

inferred from DOI database lookup

PCR-monitoring of minimal residual leukaemia after conventional chemotherapy and bone marrow transplantation in BCR-ABL-positive acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

7 January 2021

based on heuristic

inferred from DOI database lookup

Good correlation between RT-PCR analysis and relapse in Philadelphia (Ph1)-positive acute lymphoblastic leukemia (ALL)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

7 January 2021

based on heuristic

inferred from DOI database lookup

Real-time quantitation of bcr-abl transcripts in haematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

7 January 2021

based on heuristic

inferred from DOI database lookup

Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

7 January 2021

based on heuristic

inferred from DOI database lookup

Monitoring of BCR-ABL expression using real-time RT-PCR in CML after bone marrow or peripheral blood stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403062

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/SJ.LEU.2403062

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

4 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44582795&oldid=2206761301"